biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (2881)	2/21/2012 3:31:37 PM
From: tuck	Read Replies (1) of 3661

Chelsea (CHTP) off ~20% on release of FDA briefing docs that don't look very good. Now they are public. Chelsea had bounced some after they revealed what happened. The issue is safety versus efficacy. Northera works, apparently, but only for about a week, and there were bad events during the trials. The question of how much was drug related is not well established, and the FDA docs signal considerable caution here. On the other hand, this is an unmet need. The one approved drug on the market doesn't really seem to work at all and is reportedly going to be pulled in this indication. And on the other hand, the indication is probably not life threatening enough to make this risk-reward worth it. I think the panel is on Thursday. It doesn't look likely. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next